Fandom

Psychology Wiki

Dihydroergotamine

34,203pages on
this wiki
Add New Page
Talk0 Share

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)


Dihydroergotamine chemical structure
Dihydroergotamine


IUPAC name
CAS number
511-12-6
ATC code

N02CA01

PubChem
10531
DrugBank
APRD00476
Chemical formula {{{chemical_formula}}}
Molecular weight 583.678 g/mol
Bioavailability
Metabolism
Elimination half-life 9 hours
Excretion Bile
Pregnancy category
Legal status
Routes of administration


Dihydroergotamine is an ergot alkaloid used to treat migraines.

See alsoEdit

ReferencesEdit

  • Boucharlat, J., & et al. (1980). Ergotism in psychiatric environment through DHE and erythromycin propionate association: One observation: Annales Medico-Psychologiques Vol 138(3) Mar 1980, 292-296.
  • D'Alessandro, R. (1992). Intermittent prophylaxis of menstrual migraine: A pilot study with a timed-release pharmacological formulation of dihydroergotamine. Madison, CT: International Universities Press, Inc.
  • Danjou, P., Lacomblez, L., Warot, D., & Puech, A. J. (1989). Effects of dihydroergotamine on psychomotor function, neuroendocrine parameters and blood pressure, in healthy volunteers: International Clinical Psychopharmacology Vol 4(1) Jan 1989, 71-84.
  • Drakic, B., & Bukelic, J. (1980). Clinical experience in the treatment of migraine and vasomotor headache with ditamin (dehydroergotaminsulphate): Psihijatrija Danas Vol 12(1) 1980, 91-104.
  • Edwards, K. R., Norton, J., & Behnke, M. (2001). Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache: Headache: The Journal of Head and Face Pain Vol 41(10) Nov-Dec 2001, 976-980.
  • Ford, R. G., & Ford, K. T. (1997). Continuous intravenous dihydroergotamine in the treatment of intractable headache: Headache: The Journal of Head and Face Pain Vol 37(3) Mar 1997, 129-136.
  • Goadsby, P. J., & Edvinsson, L. (1993). The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats: Annals of Neurology Vol 33(1) Jan 1993, 48-56.
  • Gomez, E. (1977). Clinical observations in the treatment of tardive dyskinesia with dihydrogenated ergot alkaloids (Hydergine): Preliminary findings: Psychiatric Journal of the University of Ottawa Vol 2(2) Jul 1977, 67-71.
  • Lalanne, J., & Bouttier, S. (1972). Side effects induced by psychotropic medications and dihydroergotamine correction: Psychologie Medicale Vol 4(3) 1972, 529-537.
  • Leandri, M., Rigardo, S., Nizzo, R., Censori, B., & et al. (1991). Efficacy of programmed-release dihydroergotamine for the prevention of migraine attacks: Study of dosage schemes: Giornale di Neuropsicofarmacologia Vol 13(2) Mar-Apr 1991, 59-62.
  • Linder, S. L. (1994). Treatment of childhood headache with dihydroergotamine mesylate: Headache: The Journal of Head and Face Pain Vol 34(10) Nov-Dec 1994, 578-580.
  • Lucchelli, A., & Grana, E. (1983). Behavioural effects of chronic dihydroergocristine treatment: IRCS Medical Science: Psychology & Psychiatry Vol 11(1-2) Jan-Feb 1983, 53-54.
  • McBeath, J. G., & Nanda, A. (1994). Use of dihydroergotamine in patients with postconcussion syndrome: Headache: The Journal of Head and Face Pain Vol 34(3) Mar 1994, 148-151.
  • Pauget, J. D. (1972). Treatment with dihydroergotamine Sandoz side-effects of psychotropes: Psychologie Medicale Vol 4(4) 1972, 821-829.
  • Pericic, D., Manev, H., Levanat, S., Jernej, B., & et al. (1986). Effect of dihydroergosine (DHESN) on the serotoninergic system and behaviour: Is DHESN a new antidepressive agent? : Psychopharmacology Vol 90(1) Aug 1986, 112-118.
  • Pradalier, A., Lutz, G., & Vincent, D. (2000). Transient global amnesia, migraine, thalamic infarct, dihydroergotamine, and sumatriptan: Headache: The Journal of Head and Face Pain Vol 40(4) Apr 2000, 324-327.
  • Queiroz, L. P., Weeks, R. E., Rapoport, A. M., Sheftell, F. D., Baskin, S. M., & Siegel, S. E. (1996). Early and transient side effects of repetitive intravenous dihydroergotamine: Headache: The Journal of Head and Face Pain Vol 36(5) May 1996, 291-294.
  • Saper, J. R., & Silberstein, S. (2006). Pharmacology of Dihydroergotamine and Evidence for Efficacy and Safety in Migraine: Headache: The Journal of Head and Face Pain Vol 46(Suppl 4) Nov 2006, S171-S181.
  • Saper, J. R., Silberstein, S., Dodick, D., & Rapoport, A. (2006). DHE in the Pharmacotherapy of Migraine: Potential for a Larger Role: Headache: The Journal of Head and Face Pain Vol 46(Suppl 4) Nov 2006, S212-S220.
  • Schulman, E. A., & Rosenberg, S. B. (1991). Claudication: An unusual side effect of DHE administration: Headache: The Journal of Head and Face Pain Vol 31(4) Apr 1991, 237-239.
  • Silberstein, S. D., Schulman, E. A., & Hopkins, M. M. (1990). Repetitive intravenous DHE in the treatment of refractory headache: Headache: The Journal of Head and Face Pain Vol 30(6) May 1990, 334-339.
  • Silberstein, S. D., & Silberstein, J. R. (1992). Chronic daily headache: Long-term prognosis following inpatient treatment with repetitive IV DHE: Headache: The Journal of Head and Face Pain Vol 32(9) Oct 1992, 439-445.
  • Slanska, J. (1989). Controlled study of dihydroergotoxine in gerontopsychiatric patients: Activitas Nervosa Superior Vol 31(1) Apr 1989, 53-55.
  • Touchon, J., Bertin, L., Pilgrim, A. J., Ashford, E., & et al. (1996). A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine: Neurology Vol 47(2) Aug 1996, 361-365.
  • Ullrich, R., de Muynck, R. U., Peikert, V., & Crombach, G. (1975). Multiple treatments for agoraphobia through habituation training (flooding) and peripheral limitation of excitement: Zeitschrift fur Klinische Psychologie Vol 4(3) 1975, 209-233.
  • Weisz, M. A., El-Raheb, M., & Blumenthal, H. J. (1994). Home administration of intramuscular DHE for the treatment of acute migraine headache: Headache: The Journal of Head and Face Pain Vol 34(6) Jun 1994, 371-373.
  • Wheeler, S. D. (1993). Dihydroergotamine local reactions reduced by normal saline: Neurology Vol 43(9) Sep 1993, 1852.
  • Winner, P., Dalessio, D., Mathew, N., Sadowsky, C., & et al. (1993). Office-based treatment of acute migraine with dihydroergotamine mesylate: Headache: The Journal of Head and Face Pain Vol 33(9) Oct 1993, 471-475.
  • Ziegler, D. K., Ford, R., Kriegler, J., Gallagher, R. M., & et al. (1994). Dihydroergotamine nasal spray for the acute treatment of migraine: Neurology Vol 44(3) Mar 1994, 447-453.


Template:Antimigraine preparations

This page uses Creative Commons Licensed content from Wikipedia (view authors).

Ad blocker interference detected!


Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.

Also on Fandom

Random Wiki